Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Three Period, Fixed Sequence Study to Assess the Effect of a Single Dose of BIA 5 1058 200 mg on the Steady State Pharmacokinetics of Treprostinil in Healthy Subjects Under Fed Conditions

Next Previous
X
Search
Trial Profile

An Open-Label, Three Period, Fixed Sequence Study to Assess the Effect of a Single Dose of BIA 5 1058 200 mg on the Steady State Pharmacokinetics of Treprostinil in Healthy Subjects Under Fed Conditions

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Treprostinil (Primary) ; Zamicastat (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Pharmacokinetics
  • Sponsors BIAL - Portela C S.A.

    • Most Recent Events

    • 19 May 2021 Results assessing the effect of single dose of zamicastat on the steady-state pharmacokinetics of treprostinil and the effect of treprostinil on the pharmacokinetics of zamicastat under fed conditions and the safety of the drugs, presented at the 117th International Conference of the American Thoracic Society.
    • 23 Dec 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top